NYSE:MRKPharmaceuticals
Merck (MRK) Margins At 28.1% Reinforce Bullish Earnings Narrative Heading Into Q1 2026
Merck (MRK) has opened Q1 2026 earnings season with a reminder of its recent scale, coming off Q4 2025 revenue of about US$16.4 billion and basic EPS of US$1.19, alongside trailing 12 month EPS of roughly US$7.30 on revenue of around US$65.0 billion. Over recent quarters the company has seen revenue move between roughly US$15.3 billion and US$17.3 billion per quarter, while quarterly EPS has ranged from about US$1.19 to US$2.32. This performance has been supported by trailing 12 month net...